Efgartigimod in Sjögren’s disease: a phase 2, randomised, placebo-controlled, parallel-group, double-blinded, proof-of-concept study (RHO)

Journal:
Annals of the Rheumatic Diseases
Published:
DOI:
10.1016/j.ard.2026.03.019
Affiliations:
5
Authors:
16
Go to article
Institutions Authors Share
Argenx SE, Belgium
6.000000
 0.38
VIB-UGent Center for Inflammation Research (IRC), Belgium
4.000000
 0.25
University Medical Center Groningen (UMCG), RUG, Netherlands
4.000000
 0.25
IQVIA, United States of America (USA)
2.000000
 0.13
Interested in Neurosciences?